MacroGenics
MGNX
111 hedge funds and large institutions have $537M invested in MacroGenics in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 38 reducing their positions, and 25 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 38
0.83% less ownership
Funds ownership: 83.41% → 82.58% (-0.83%)
5% less call options, than puts
Call options by funds: $416K | Put options by funds: $440K
10% less capital invested
Capital invested by funds: $594M → $537M (-$56.7M)
15% less funds holding
Funds holding: 131 → 111 (-20)
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$47.7M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$6.56M |
| 3 |
O
OppenheimerFunds
New York
|
+$5.52M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$4.27M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.44M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.71M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.67M |
| 5 |
First Eagle Investment Management
New York
|
-$3.58M |
MGNX Hedge Fund Activity: Q1 2017 in Review
111 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q1 2017, worth a combined $537M — down 9.5% from $594M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MGNX and 11 opened new positions — a net loss of 14 holders — while 38 trimmed existing stakes and 38 added.
The largest buyer was BlackRock, adding an estimated $47.7M. The largest seller was Eventide Asset Management, cutting an estimated $11.2M.
- 111 institutional investors held MacroGenics (MGNX) as of Q1 2017, down from 131 in Q4 2016.
- Funds reported $537M of MacroGenics stock for Q1 2017, down 9.5% quarter-over-quarter.
- 11 funds opened new MacroGenics positions in Q1 2017 and 25 closed out, a net change of -14 holders.
- The largest MacroGenics buyer in Q1 2017 was BlackRock, an estimated $47.7M added.
- The largest MacroGenics seller in Q1 2017 was Eventide Asset Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2017.